Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis
The DOI matches its OpenAlex record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe drugs in the treatment of endometriosis. Nevertheless, gestagens such as lynestrenol still remain the most often used hormonal drugs for the treatment of this disease. The primary objective of this study was to compare the efficacy of the GnRH-agonist leuprorelin acetate depot (LAD) (Enantone-Gyn) 3.75 mg subcutaneously per month with that of the gestagen lynestrenol (LYN) (Orgametril) 5 mg orally twice per day in women with severe endometriosis, in terms of postoperative revised American Fertility Society (r-AFS) scores I-IV at first-look laparoscopy (score after removal of endometriotic lesions or adhesions) to the r-AFS score after six months' treatment. Secondary objectives were the improvement of clinical symptoms and the side-effect profile. Forty-eight women with postoperative r-AFS scores I-IV were evaluated in an open prospective randomized study between 1996 and 1998. All the participants underwent a first-look laparoscopy with resection of endometriotic lesions and six months' therapy with one of the above mentioned drugs, and a further second-look laparoscopy. The six months' treatment with LAD or LYN led to a significant reduction of the r-AFS score points in both groups. The mean r-AFS score in points for the LAD group after the first-look laparoscopy was 21.8 and was 27.2 for the LYN group. After the medical treatment a mean value of 11.5 points was observed in the LAD group compared with a mean value of 25.5 in the LYN group. This difference was statistically significant (p = 0.000014, Wilcoxon test). The improvement in the symptoms of dysmenorrhea, chronic pelvic pain and dyspareunia was also more pronounced in the LAD-treated group. LAD was more effective than LYN in the suppression of circulating serum 17 beta-estradiol levels after 6 months of treatment (mean 27.7 +/- 9.3 pg/ml versus 42.6 +/- 59.3 pg/ml). All the observed side-effects were deemed tolerable by the women who participated in this study. As the reduction of the r-AFS score in points was much more pronounced in the LAD group than in the LYN group, GnRH-agonists should therefore be used as first-choice drugs in the treatment of endometriosis. Due to the limited treatment of 6 months' duration of GnRH-agonists, gestagens might be used as second-line drugs for long-term and continuous treatment in the management of endometriosis to maintain the primary beneficial effect of GnRH-agonist treatment in patients who have completed their families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Revised American Fertility Society Classification of Endometriosis: 1985
(1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48430-x · Cited by 1,803
Dlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Shaw, R. W. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55205-4 · Cited by 119
Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis
Wheeler, J. M., Knittle, J. D., & Miller, J. D. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)91718-9 · Cited by 106
Combined (hormonal and microsurgical) therapy in infertile women with endometriosis
Donnez, J., Lemaire-Rubbers, M., Karaman, Y., Nisolle-Pochet, M., & Casanas-Roux, F. (1987) · Fertility and Sterility · doi:10.1016/s0015-0282(16)59349-2 · Cited by 54
Cited by
Progestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
Progestogens for endometriosis: forward to the past
Vercellini, P. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg030 · Cited by 147
“…treatment with the progestogen lynestrenol (10 mg/day post-operatively) were compared with those of the GnRH leuprolide depot formulation (3.75 mg monthly s.c. injections) in a randomized study conducted on 48 women who had undergone operative laparoscopy for endometriosis (Regidor et al., 2001).”
InfluentialDoyle, J. O., Missmer, S. A., & Laufer, M. R. (2009) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2008.11.003 · Cited by 84
Wu, L., Wu, Q., & Liu, L. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.819085 · Cited by 32
Metadata
- Authors
- Regidor, P., Regidor, M., Schmidt, M., Ruwe, B., Lübben, G., Förtig, P., Kienle, E., & Schindler, A. E.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa
- Published
- 2001-01-01
- Volume
- 15
- Issue
- 3
- Pages
- 202-209
- ISSN
- 0951-3590 (ISSN-L)
- OpenAlex
- W1973104602
- Cited by
- 56
- References
- 7
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.